Bronchial artery embolization controls massive hemoptysis in 75–90% of cases. Learn the complete IR protocol, imaging parameters, and radiation safety strategies.

Bronchial Artery Embolization: 7-Step IR Protocol for Massive Hemoptysis

Introduction

Bronchial artery embolization is a cornerstone interventional radiology procedure for controlling life-threatening hemoptysis. When a patient expectorates more than 100–600 mL of blood within 24 hours, mortality can exceed 50% without definitive intervention [5]. BAE offers a minimally invasive alternative to emergent thoracotomy, achieving hemostasis through selective occlusion of hypertrophied bronchial arteries and systemic collaterals.

The procedure demands meticulous attention to vascular anatomy, particularly the identification of spinal artery origins that may arise from bronchial or intercostal vessels [3]. Modern cone-beam CT (CBCT) and high-resolution DSA have transformed the safety profile of BAE, enabling superselective catheterization and reducing the risk of devastating neurological complications [6].

Indications and patient selection

BAE is indicated for massive hemoptysis defined as >100–600 mL per 24 hours, moderate recurrent hemoptysis exceeding 30 mL daily for more than one week, and any hemoptysis with documented abnormal bronchial arteries on CTA [1][5]. Common underlying pathologies include tuberculosis, aspergilloma, bronchiectasis, cystic fibrosis, lung malignancy, and necrotizing pneumonia [8].

Patient selection requires a multidisciplinary approach involving pulmonology, thoracic surgery, and interventional radiology. Hemodynamic stability is preferred but not absolute; transient responders with ongoing bleeding despite resuscitation may still benefit from emergent BAE if surgical backup is available [9]. Pre-procedure CTA of the chest is strongly recommended to map bronchial artery origins, identify aneurysmal vessels, and detect non-bronchial systemic contributors [10].

Bronchial artery anatomy and variants

Bronchial arteries typically arise from the descending thoracic aorta at the T5–T6 vertebral level. The classic pattern consists of two left bronchial arteries and one right bronchial artery, though significant variation is common [3]. The left bronchial arteries most frequently originate directly from the aorta, while the right bronchial artery may share a common trunk with an intercostal artery, forming a bronchointercostal trunk [11].

Non-bronchial systemic arteries contributing to pulmonary hemorrhage include intercostal, internal mammary, inferior phrenic, and subclavian branches [4]. These vessels must be investigated when bronchial angiography fails to identify the bleeding source or when post-embolization recurrence occurs. The anterior spinal artery and radiculomedullary branches represent the most critical anastomoses; inadvertent embolization of these vessels can cause transverse myelitis [12].

Imaging parameters and contrast protocols

Digital subtraction angiography (DSA) remains the gold standard for BAE guidance. Frame rates of 3–6 fps are recommended to capture rapid arterial filling and early venous shunting [6]. Pre-procedure CTA with 1 mm slice thickness and arterial-phase acquisition provides a roadmap of bronchial artery origins, course, and anastomoses [10].

Contrast administration protocols vary by injection site. A thoracic aortogram requires 20–30 mL of non-ionic iodinated contrast injected at 15–20 mL/s [13]. Selective bronchial artery injections use smaller volumes of 3–5 mL at 1–2 mL/s to minimize reflux and nontarget exposure [2]. CBCT angiography with 6–8 mL at 2 mL/s offers three-dimensional visualization of culprit vessels and nontarget branches before embolization [6].

Equipment and embolic selection

Standard 5F diagnostic catheters such as the Cobra, Imari, or Simmons shapes provide stable seating in the descending aorta for bronchial artery cannulation [2]. A 2.4F microcatheter (e.g., Progreat) is essential for superselective embolization distal to dangerous anastomoses [14]. Hydrophilic 0.035-inch wires facilitate navigation through tortuous vessels.

Embolic agents for BAE include polyvinyl alcohol (PVA) particles sized 300–500 μm, microcoils for proximal occlusion, and liquid embolics such as Onyx or N-butyl cyanoacrylate (NBCA) for high-flow arteriovenous malformations [15]. Particles smaller than 300 μm should be avoided due to the risk of spinal cord ischemia [3]. Gel foam slurry offers a temporary option when future revascularization is anticipated, though recurrence rates are higher [16].

Step-by-step procedural protocol

Step 1: Patient positioning and access

Place the patient in the supine position with lateral decubitus tilt toward the bleeding side if known. Obtain right common femoral artery access with a 4–5F vascular sheath. Administer moderate sedation and establish continuous hemodynamic monitoring [2].

Step 2: Aortography and roadmap

Perform a thoracic aortogram at the T5–T6 level to identify all bronchial artery origins and variant anatomy. Create a roadmap for selective catheterization [13].

Step 3: Selective catheterization

Engage each bronchial artery with a diagnostic catheter. Perform gentle hand injections of 2–3 mL contrast to assess flow characteristics and identify hypertrophied vessels with hypervascular blush or pseudoaneurysm [2].

Step 4: CBCT and spinal artery assessment

Before embolization, acquire CBCT or perform high-resolution DSA to exclude radiculomedullary branches. If a spinal artery is identified, abandon the vessel or use a microcatheter to bypass the origin [12].

Step 5: Superselective embolization

Advance a microcatheter as distally as possible. Inject PVA particles (300–500 μm) slowly at 0.5–1 mL/min under continuous fluoroscopy until stasis is achieved [15]. Avoid complete occlusion to prevent reflux.

Step 6: Post-embolization angiography

Confirm elimination of the pathologic blush and absence of antegrade flow. Document all embolized vessels and any residual feeders [1].

Step 7: Recovery and monitoring

Remove the sheath and achieve hemostasis. Transfer to a monitored setting. Maintain lateral decubitus positioning with the bleeding side down for 4–6 hours [9].

Radiation dose reduction and personnel safety

BAE procedures often require prolonged fluoroscopy and multiple DSA runs, resulting in significant radiation exposure to both patients and personnel [15]. The ALARA principle must guide every technical decision. Collimate tightly to the thoracic field, minimize the number of angiographic runs, and use last-image hold rather than additional fluoroscopy for roadmap confirmation [17].

Personnel protection is paramount during BAE. All staff in the angiography suite must wear 0.5 mm lead-equivalent aprons with wraparound skirts, thyroid shields, and leaded eyewear [18]. The operator’s hands are particularly vulnerable during prolonged microcatheter manipulation under fluoroscopy. SATPro 0.5 mm Pb leaded gloves reduce extremity dose by up to 60% during superselective catheterization [19].

SATPro ceiling-mounted scatter-shield systems and table-side lead drapes attenuate scattered radiation by approximately 70% at the operator’s standing position [20]. For BAE specifically, where the X-ray tube is often positioned beneath the table, SATPro disposable sterile lead-equivalent scatter-shield drapes placed along the patient’s lateral thorax protect the operator from lateral scatter during oblique projections [21].

Additional dose-reduction measures include pulsed fluoroscopy at the lowest acceptable frame rate, spectral beam filtration, and the use of anti-scatter grids appropriate for patient body habitus [17]. SATPro wireless real-time dosimetry badges enable continuous monitoring of staff exposure, with automated alerts when cumulative dose approaches institutional thresholds [22]. Institutional quality assurance programs should review dose metrics after every BAE case to identify optimization opportunities.

Outcomes and recurrence predictors

Immediate bleeding control after BAE is achieved in 75–90% of patients, with technical success reported at 90–95% [1][2]. However, recurrence occurs in 10–30% of cases within 1–3 years, driven by recanalization of embolized vessels or recruitment of new systemic collaterals [5].

Predictors of recurrence include aspergilloma, active tuberculosis, cystic fibrosis, and incomplete initial embolization [8]. Patients with non-bronchial systemic artery feeders experience higher recurrence rates if these vessels are not identified and treated during the index procedure [4]. Early re-bleeding within 30 days often indicates incomplete embolization or a missed feeder and warrants repeat angiography [7].

Complications and avoidance strategies

The most feared complication of BAE is spinal cord ischemia, occurring in 1–5% of cases when spinal artery origins are not recognized [3]. Transverse myelitis presents as delayed-onset paraplegia and carries a devastating prognosis. Meticulous pre-embolization angiographic assessment and the use of CBCT have reduced this risk substantially [12].

Other complications include chest pain from post-embolization syndrome (20–30%), dysphagia from esophageal branch embolization, nontarget embolization to coronary or cerebral territories (rare), and aortic dissection from aggressive catheter manipulation [2]. Fever and leukocytosis are expected for 24–48 hours after particle embolization and should not be mistaken for infection [16].

Follow-up and re-intervention

Clinical follow-up should occur at 1 week, 1 month, and 3 months after BAE. Chest CTA is indicated if recurrence is suspected or if new hemoptysis develops [10]. Bronchoscopy may be required to exclude endobronchial sources of bleeding not amenable to embolization [9].

Repeat BAE is technically feasible and clinically effective in selected patients with recurrent hemoptysis. However, patients with aspergilloma or cavitary lung cancer may ultimately require surgical resection or definitive radiation therapy for durable control [8]. Long-term management of the underlying disease remains essential to preventing future bleeding episodes.

Conclusion

Bronchial artery embolization is a life-saving intervention for massive hemoptysis, delivering immediate hemostasis in the majority of patients while avoiding the morbidity of emergent thoracotomy. Success depends on thorough pre-procedure CTA planning, meticulous spinal artery assessment, superselective embolization technique, and comprehensive radiation protection for the interventional team. By integrating SATPro scatter-shield systems, leaded eyewear, and real-time dosimetry into routine practice, operators can sustain high procedural volumes without compromising long-term occupational safety. Mastery of BAE represents a defining competency for the modern interventional radiologist.